SAN

82.62

-0.28%↓

MRK1

118.4

+0.94%↑

SHL.DE

43.28

+0.37%↑

ARGX

757.6

-1.74%↓

FRE

48.08

+1.71%↑

SAN

82.62

-0.28%↓

MRK1

118.4

+0.94%↑

SHL.DE

43.28

+0.37%↑

ARGX

757.6

-1.74%↓

FRE

48.08

+1.71%↑

SAN

82.62

-0.28%↓

MRK1

118.4

+0.94%↑

SHL.DE

43.28

+0.37%↑

ARGX

757.6

-1.74%↓

FRE

48.08

+1.71%↑

SAN

82.62

-0.28%↓

MRK1

118.4

+0.94%↑

SHL.DE

43.28

+0.37%↑

ARGX

757.6

-1.74%↓

FRE

48.08

+1.71%↑

SAN

82.62

-0.28%↓

MRK1

118.4

+0.94%↑

SHL.DE

43.28

+0.37%↑

ARGX

757.6

-1.74%↓

FRE

48.08

+1.71%↑

Home・Aandelen Lijst・Pharming Group NV

P
Pharming Group NV

Open

1.456 1.04

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.43

Max

1.475

Belangrijke statistieken
By Trading Economics
Inkomsten	2.9M 7.5M
Verkoop	4.1M 97M
EPS	0.009
Winstmarge	7.758
Werknemers	404

Marktinformatie
By TradingEconomics
Marktkapitalisatie	685K 998M
Vorige openingsprijs	0.42
Vorige sluitingsprijs	1.456

Pharming Group NV Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 dec 2025, 22:02 UTC

Winsten

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

10 dec 2025, 21:46 UTC

Winsten

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

10 dec 2025, 23:52 UTC

Acquisities, Fusies, Overnames

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

10 dec 2025, 23:43 UTC

Marktinformatie

Nikkei May Rise After Fed Rate Cut -- Market Talk

10 dec 2025, 23:36 UTC

Marktinformatie

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

10 dec 2025, 23:20 UTC

Winsten

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

10 dec 2025, 23:15 UTC

Winsten

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

10 dec 2025, 22:59 UTC

Marktinformatie

Winsten

Acquisities, Fusies, Overnames

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

10 dec 2025, 22:45 UTC

Marktinformatie

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

10 dec 2025, 22:40 UTC

Winsten

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 dec 2025, 22:06 UTC

Acquisities, Fusies, Overnames

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 dec 2025, 22:06 UTC

Winsten

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 dec 2025, 22:02 UTC

Winsten

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 dec 2025, 22:00 UTC

Winsten

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

10 dec 2025, 21:53 UTC

Winsten

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 dec 2025, 21:50 UTC

Acquisities, Fusies, Overnames

Investors Bet That a Higher Bid for Warner Is Coming -- Update

10 dec 2025, 21:50 UTC

Marktinformatie

Winsten

Acquisities, Fusies, Overnames

Financial Services Roundup: Market Talk

10 dec 2025, 21:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

10 dec 2025, 21:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

10 dec 2025, 21:45 UTC

Acquisities, Fusies, Overnames

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 dec 2025, 21:33 UTC

Winsten

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

10 dec 2025, 21:32 UTC

Winsten

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 dec 2025, 21:28 UTC

Acquisities, Fusies, Overnames

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

10 dec 2025, 21:25 UTC

Winsten

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 dec 2025, 21:18 UTC

Acquisities, Fusies, Overnames

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

10 dec 2025, 21:16 UTC

Winsten

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

10 dec 2025, 21:15 UTC

Acquisities, Fusies, Overnames

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

10 dec 2025, 21:15 UTC

Winsten

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

10 dec 2025, 21:14 UTC

Winsten

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

10 dec 2025, 21:14 UTC

Winsten

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

Peer Vergelijking

Prijswijziging

Pharming Group NV Prognose

Beoordelingsconsensus

By TipRanks

0 ratings

Buy

Hold

Sell

Gebaseerd op 0 analisten die aandelenratings hebben gegeven aan Pharming Group NV - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.